New thrombin and factor Xa inhibitors for primary and secondary prevention of Ischaemic stroke

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 242-251

  Winstanley, Lisa ^a   Chen, Ruoling ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anticoagulant; Antithrombotic; Atrial fibrillation; Factor Xa inhibitors; Ischaemic stroke; Primary and secondary stroke prevention; Thrombin inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; APIXABAN; ATECEGATRAN METOXIL; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DAREXABAN; DU 1766; EDOXABAN; PLACEBO; RIVAROXABAN; S 35972; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

BLEEDING; BRAIN ISCHEMIA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HEART ATRIUM FIBRILLATION; LIVER DISEASE; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; ENZYME INHIBITORS; FACTOR XA; HUMANS; STROKE; THROMBIN;

EID: 84876732997     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273112119990051     Document Type: Review

References (76)

1. Mathers, C.D.; Loncar, C. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 2006, 3(11), e442.
2. Johnson, S.C.; Mendis, S.; Mathers, C.D. Global variation in stroke burden and mortality; estimates from monitoring, surveillance, and modelling. Lancet Neurol., 2009, 8(4), 345-354.
3. Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991, 22(8), 983-988.
4. Hart, R.G.; Pearce, L.A.; Aguilar, M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med., 2007, 146(12), 857-867.
5. Ahrens, I.; Lip, G.Y.H.; Peter, K. New oral anticoagulant drugs in cardiovascular disease. Thromb. Haemost., 2010, 104(1), 49-60.
6. Ansell, J.; Hirsch, J.; Hylek, E.; Jacobsen, A.; Crowther, M.; Palareti, G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 2008, 133(6 Suppl), 160s-198s.
7. European Atrial Fibrillation Trial (EAFT). Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet, 1993, 342(8882), 1255-1262.
8. Hylek, E.; Singer, D. Risk factors for intracranial hemorrhage in outpatientstaking warfarin. Ann. Intern. Med., 1994, 120(11), 897-902.
9. Man-Son-Hing, M.; Laupacis, A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch. Intern. Med., 2003,163(13), 1580-1586.
10. Merli, G.; Weitz, H.H. The decision to anticoagulate: assessing whether benefits outweigh the risks for patients with atrial fibrillation. Clin. Cardiol., 2004, 27(6), s13-s20.
11. Singer, D.E.; Chang, Y.; Fang, M.C.; Borowsky, L.H.l; Pomemacki, N.K.; Udaltsova, N.; Go, A.S. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med., 2009, 151(5), 297-305.
12. Rupin, A.; Marx, I.; Vallez, M.O. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. J. Thromb. Haemost., 2011, 9(7), 1375-1382.
13. Olsson, S.B.; Rasmussen, L.H.; Tveit, A.; Jesen, E.; Wessman, P.; Panifilov, S.; Wahlander, K. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb. Haemost., 2010, 103(3), 604-612.
14. Stangier, J.; Rathgen, K.; Stahle, H.; Gansser, D.; Roth, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol., 2007, 64(3), 292-303.
15. Eriksson, B.I.; Quinlan, D.J.; Weitz, J.I. Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. Clin. Pharmacokinet., 2009, 48(1), 1-22.
16. Olsson, S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Executive Steering Committee on behalf of the SPORTIF III Investigators, editor. Lancet, 2003, 362(9397),1691-1698.
17. Albers, G.W.; Diener, H.C.; Frison, L.; Grind, M.; Nevinson, M.; Partridge, S.; Halperin, J.L.; Horrow, J.; Olsson, S.B.; Petersen, P.; Vahanian, A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. SPORTIF Executive Steering Committee for the SPORTIF V Investigations, editor. JAMA, 2005, 293(6), 690-698.
18. Diener, H.C. Executive Steering Committee of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Executive Steering Committee of the SPORTIF III and V Investigators, editor. Cerebrovasc. Dis., 2006, 21(4), 279-293.
19. Ford, G.A.; Choy, A.M.; Deedwania, P.; Karalis, D.G.; Lindholm, C.J.; Pluta, W.; Frison, L.; Olsson, S.B. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation, Experience from the SPORTIF III and V trials. on behalf of the SPORTIF III VI, editor. Stroke, 2007, 38(11), 2965-2971.
20. Lee, W.M.; Larrey, D.; Olsson, R.; Lewis, J.H.; Keisa, M.; Auclert, L.; Shoth, S. Hepatic findings in long-term clinical trials of ximelagatran. Drug Safety, 2005, 28(4), 351-370.
21. Blech, S.; Ebner, T.; Ludwig-Schwellinger, E.; Stangier, J.; Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos., 2008, 36(2), 386-399.
22. Pradaxa - Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules/ (accessed August 01, 2012).
23. Ufer, M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost., 2010, 103(3), 572-585.
24. Ezekowitz, M.D.; Reilly, P.A.; Nehmiz, G.; Simmers, T.A.; Naqarakanti, R.; Parcham-Azad, K.; Pedersen, K.E.; Lionetti, D.A.; Stangier, J.; Wallentin, L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol., 2007, 100(9), 1419-1426.
25. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; Wang, S.; Alings, M.; Xavier, D.; Zhu, J.; Diaz, R.; Lewis, B.S.; Darius, H.; Diener, H.C.; Joyner, C.; Wallentin, L.; RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med., 2009, 361(12), 1139-1151.
26. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; Wang, S.; Alings, M.; Xavier, D.; Zhu, J.; Diaz, R.; Lewis, B.S.; Darius, H.; Diener, H.C.; Joyner, C.; Wallentin, L.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 363(19), 1877.
27. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Reilly, P.A.; Wallentin, L. RE-LY Investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med., 2012, 363(9), 1157-1163.
28. Diener, H.C.; Connolly, S.J.; Ezekowitz, M.D.; Wallentin, L.; Reilly, P.A.; Yang, S.; Xavier, D.; Di Pasquale, G.; Yusuf, S.; RELY Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet, 2010, 9(12), 1157-1163.
29. Nagarakanti, R.; Ezekowitz, M.D.; Oldgren, J.; Yang, S.; Chernick, M.; Aitkens, T.H.; Flaker, G.; Brugada, J.; Kamensky, G.; Parekh, A.; Reilly, P.A.; Yusuf, S.; Connolly, S.J. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation, 2011, 123(2), 131-136.
30. Roskell, N.S.; Lip, G.Y.; Noack, H.; Clemens, A.; Plumb, J.M. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb. Haemost., 2010, 104(6), 1106-1115. 2010.
31. RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RELY Trial. http://clinicaltrials.gov/ct2/show/NCT00808067 (accessed April 10, 2012).
32. Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; Prendergast, B.; Heidbuchel, H. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 2010, 31(19), 2369-2429.
33. Cairns, J.A.; Connolly, S.; McMurtry, S.; Stephenson, M.; Talajic, M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. CCS Atrial Fibrillation Guidelines Committee, editor. Can. J. Cardiol., 2011, 27(1), 74-90.
34. Wann, L.S.; Curtis, A.B.; January, C.T.; Ellenbogen, K.A.; Lowe, C.E.; Estes, N.A.M.; Page, R.L.; Ezekowitz, M.D.; Slotwiner, D.J.; Jackman, W.M.; Stevenson, W.G.; Tracy, C.M.; Fuster, V. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011, 123(1), 104-123.
35. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance. Available at: http://publications.nice.org.uk/dabigatran-etexilate-for-the-prevention-of-stroke-andsystemic-embolism-in-atrial-fibrillation-ta249/guidance (accessed April 17, 2012).
36. U.S. Department of Health & Human Services. FDA aproves Paradaxa to prevent stroke in people with atrial fibrillation. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm (accessed March 28, 2012).
37. Medical News Today. PRADAX™ (Dabigatran Etexilate) Gains Approval In Canada For Stroke Prevention In Atrial Fibrillation. Available at: http://www.medicalnewstoday.com/releases/205933.php (accessed March 28, 2012).
38. Available at: http://www.theheart.org/article/1260249.do (accessed March 28, 2012).
39. Lip, G.Y.; Rasmussen, L.H.; Olsson, S.B.; Jensen, E.C.; Persson, A.L.; Eriksson, U.; Wahlander, K.F.C. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur. Heart J., 2009, 30(23), 2897-2907.
40. http://www.trialresultscenter.org/study (accessed March 21, 2012).
41. Kubitza, D.; Becka, M.; Voith, B.; Zuehlsdorf, M.; Wensing, G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther., 2005, 78(4), 412-421.
42. Weinz, C.; Schwarz, T.; Kubitza, D.; Mueck, W.; Lang, D. Metabolism and excretion of rivaroxaban,an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab. Dispos., 2009, 37(5),1056-1064.
43. Mismetti, P.; Laporte, S. Rivaroxaban: clinical pharmacology. Ann. Fr. Anesth. Reanim., 2007, 27(Suppl 3), s16-s21.
44. Perzborn, E.; Roehrig, S.; Straub, A.; Kubitza, D.; Mueck, W.; Laux, V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol., 2010, 30(3), 376-381.
45. Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; Becker, R.C.; Nessell, C.C.; Paolini, J.F.; Berkowitz, S.D.; Fox, K.A.A.; Califf, R.M. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med., 2011, 365(10), 883-891.
46. Patel, M.R. The Executive Steering Committee,on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am. Heart J., 2010, 159(3), 340-347.
47. Hacke, W.; Hankey, G. Rivaroxaban versus warfarin in patients with AF and prior cerebrovascular disease: Results from the ROCKET-AF trial. ROCKET AF Committees, editor. 2012. 2011 European Stroke Conference; May 24-27, 2011;. Hamburg, Germany
48. Fox, K.A.; Piccini, J.P.; Wojdyla, D.; Becker, R.C.; Halperin, J.L.; Nessell, C.C.; Paolini, J.F.; Hankey, G.J.; Mahaffey, K.W.; Patel, M.R.; Singer, D.E.; Califf, R.M. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur. Heart J., 2011, 32(19), 2387-2394.
49. Mueck, W.; Lensing, A.W.; Agnelli, G.; Decousus, H.; Prandoni, P.; Misselwitz, F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet., 2011, 50(10), 675-686.
50. Rocket J Study. Ongoing trial. Available at: http://www.trialresultscenter.org/study12240-ROCKET-J.htm (accessed March 21, 2012).
51. Bayer's Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT. Available at: http://www.bayer.com/en/news-detail.aspx?newsid=15486 (accessed August 01, 2012).
52. FDA approves rivaroxaban for stroke prevention in AF patients. Available at: http://www.theheart.org/article/1304213.do (accessed August 01, 2012).
53. National Institute for Health and Clinical Excellence. Atrial fibrillation (stroke prevention)-rivaroxaban (TA256). Available at: http://guidance.nice.org.uk/TA256 (accessed August 01, 2012).
54. Connolly, S.; Eikelboom, J.; Joyner, C.; Diener, H.C.; Hart, R.; Golitsyn, S.; Flaker, G.; Avezum, A.; Hohnloser, S.; Diaz, R.; Talajic, M.; Zhu, J. Apixaban in Patients with Atrial Fibrillation. N. Engl. J. Med., 2011, 364(9), 806-817.
55. Yates, S.W. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. Hosp. Pract., 2011, 39(4), 7-16.
56. Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopez, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; Bahif, C.; Diaz, R.; Easton, D.; Ezekowitz, J.A. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med., 2011, 365(11), 981-992.
57. Weitz, J.I.; Connolly, S.J.; Kunitada, S.; Jin, J.; Patel, I. Randomized, parallel group, multicentre, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation. Blood, 2008, 112, 33.
58. Ruff, C.T.; Guigliano, R.P.; Antman, E.M.; Crugnale, S.E.; Bocanegra, T.; Mercuri, M.; Hanyok, J.; Patel, I.; Shi, M.; Salazar, D.; McCabe, C.H.; Braunwald, E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J., 2010, 160(4), 635-641.
59. Portola Pharmaceuticals. Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation. Available at: http://www.portola.com/pdfs/Betrixaban_EXPLORE_ACC_032010.pdf (accessed March 30, 2012).
60. Portola Pharmaceuticals. Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin (EXPLORE-Xa). Available at: http://clinicaltrials.gov/ct2/show/NCT00742859.(accessed March 30, 2012).
61. MERCK. Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation. Available at: http://www.portola.com/pdfs/Betrixaban_EXPLORE_ACC_032010.pdf (accessed March 30, 2012)
62. Khoo, C.W.; Tay, K.H.; Shantsila, E.; Lip, G. Novel oral anticoagulants. Int. J. Clin. Pract., 2009, 63(4), 630-641.
63. Portola Pharmaceuticals. FXa Inhibitor Antidote. Available at: http://www.portola.com/PRT064445-Fxa-Inhibitor-Antidote (accessed April 4, 2012).
64. OPAL-2 study. Available at: http://www.trialresultscenter.org/study11453-OPAL-2.htm (accessed April 4, 2012).
65. Turpie, A.G.G.; Lip, G.Y.H.; Minematsu, K.; Goto, S.; Renfurm, R.W.; Wong, K.S.L. Safety and tolerability of YM150 in subjects with non-valvular atrial fibril.lation: a phase II study. Eur. Heart J., 2010.
66. Cabrall, K.P.; Ansell, J.; Hylek, E.M. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J. Thromb Haemost., 2010, 9(3), 441-449.
67. Lip, G.Y.; Larsen, T.B.; Skjøth, F.; Rasmussen, L.H. Indirect comparison of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol., 2012, 60(8), 738-746
68. White, H.D.; Gruber, M.; Feyzi, J.; Kaatz, S.; Tse, H.F.; Husted, S.; Albers, G.W. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med., 2007, 167(3), 239-245.
69. Connolly, S.J.; Pogue, J.; Eikelboom, J.; Flaker, G.; Commerford, P.; Franzosi, M.G.; Healey, J.S.; Yusuf, S.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation, 2008, 118(20), 2029-2037.
70. Hylek, E.M.; Go, S.; Chang, Y.; Jenswold, N.G.; Henault, L.E.; Selby, J.V.; Singer, D.E. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N. Engl. J. Med., 2003, 349(11), 1019-1026.
71. Garcia-Alamino, J.M.; Ward, A.M.; Alonso-Coello, P.; Perera, R.; Bankhead, C.; Fitzmaurice, D.; Heneghan, C.J. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev., 2010, (4), CD003839.
72. Bungard, T.J.; Ghali, W.A.; Teo, K.K.; McAlister, F.A.; Tsuyuki, R.T. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med., 2000, 160(1), 41-46.
73. van Ryn, J.; Stangier, J.; Haerter, S.; Liesenfeld, K.H.; Wienen, W.; Feuring, M.; Clemens, A. Dabigatran exiletate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulation activity. Stangier JHSeal, editor. Thromb. Haemost., 2010, 103(6), 1116-1127.
74. van Ryn, D.; Ruehl, D.; Priepke, H.; Hauel, N.; Weinen, W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIA or activated prothrombin complex concentrate. Haematologica, 2008, 93(Suppl 1), 148.
75. Lu, G.; DeGuzman, F.R.; Lakhotia, S.; Hollenbach, S.J.; Phillips, D.R.; Sinha, U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. Blood, 2008, 112, 362.
76. Gruber, A.; Marzer, U.M.; Buetehorn, U.; Hanson, S.R.; Perzborn, E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood, 2008, 112, 1307